Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

NCT00100906 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators